If you have been reading about TB-500 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-25. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
January 3, 2013: Decree establishing an interministerial mission for the protection of women against violence and the fight against human trafficking. January 3, 2013: Decree establishing the High Council for Gender Equality. January 31, 2013: Law repealing Law No. 2010-1127 of September 28, 2010, aimed at combating school absenteeism. May 17, 2013: Law on the election of departmental, municipal, and community councillors and modifying the electoral calendar. May 17, 2013: Law opening marriage to same-sex couples. June 19, 2013: National interprofessional agreement "Toward a policy of improving quality of life at work and professional equality." July 8, 2013: Orientation and programming law for the refoundation of the Republic's school system. July 22, 2013: Law on higher education and research, notably requiring gender parity in elections and appointments to governance bodies of institutions. August 2, 2013: Law on the election of senators, introducing measures to increase female representation. August 5, 2013: Law on various adjustments in justice according to EU law and France's international commitments. November 2013: Fourth interministerial plan for preventing and combating violence against women. December 2013: Bill on combating the prostitution system. December 27, 2013: Decree on the annual report on professional equality in the civil service. January 20, 2014: Law ensuring the future and fairness of the pension system. April 16, 2014: Decree on the responsibilities of the Minister for Women's Rights, Cities, Youth, and Sports.
==== New driver's license system ==== The National Traffic Council (Contran) approved a resolution in December 2025 ending the requirement that all theoretical and practical classes for obtaining a Brazilian driver's license (CNH) in categories A (motorcycles) and B (cars) must be taken exclusively at driving schools (CFC). The government will provide a free digital theoretical course. Practical lessons may be conducted with accredited independent instructors, including using a personal vehicle, or at driving schools. The minimum duration of lessons has been reduced from 25 hours to 2 hours. Biometric registration, theoretical and practical examinations, and medical tests remain mandatory. The reduction in costs is estimated at 70%. The Brazilian Manual of Driving Examinations was updated with unified guidelines for driving tests nationwide, eliminating parallel parking as a mandatory stage and revising the criteria for approval and failure. Each infraction now receives a specific score, and candidates are approved only if they do not exceed a limit of 10 points. The rule of a single infraction leading to immediate failure was eliminated. Beginning in January 2026, automatic and free license renewal was introduced for drivers considered to have a good record—those who have no points on their license in the previous 12 months, no recorded traffic infractions in that period, and who are registered in the National Positive Drivers Registry (RNPC). Drivers over the age of 70 are not eligible for automatic renewal, and drivers over 50 may renew automatically only once.
The "Second Indo-Iranian style" evolved with a few intermediate stages, expressing continuous influence from India, combined with influence from the Eastern Iran sphere, at that time occupied by the Sasanian Empire and the Hephthalites, with strong Sogdian cultural elements. The Hephthalites lost political power circa 550 CE after being defeated by the Sasanids and the Western Turks, but they remained influential for a long time, having fragmented into semi-independent Principalities. Sogdia, at the center of a new Silk Road between China to the Sasanian Empire and the Byzantine Empire became extremely prosperous around that time.
Sources: en.wikipedia.org
Hari Singh (1910–2003) was an Indian forestry administrator who served as the Inspector General of Forests of India from 1964 to 1969. He played a foundational role in the country's environmental governance, most notably overseeing the reconstitution of the Indian Forest Service (IFS) into an All India Service in 1966. His tenure emphasized professionalized, scientific forest management, balancing post-independence industrial demands with sustainable ecological practices.
=== High API gravity === API gravity, American Petroleum Institute gravity, is a reverse method to decide “the weight of petroleum liquids in comparison to water”. If the API gravity exceeds 10, the liquid will float on the water and is classified to light oil. Therefore, the higher API means the lighter crude oil and it is regarded as more precious than crude oil with lower API (heavier crude) as it generates more high-value products during refinery process. The API range of light crude is between 35 and 45, and BLCO has an API of 32.9.
Secretary of Treasury Scott Bessent joined the trip after having met with Chinese vice premier He Lifeng in South Korea. Within the Trump family, Trump's son Eric and his wife Lara also joined the visit. On 12 April, a spokesperson for The Trump Organisation told Reuters, Eric and Lara Trump "will accompany Trump in a personal capacity on the May 12 to 15 visit." Reuters noted that this may represent a conflict of interest, given that "Trump's personal wealth and business dealings are managed by Eric and other members of his family." Unlike in 2017, Trump's wife Melania did not join the trip. On 8 May, news circulated that a delegation of American CEOs representing the business community would join Trump on his visit. The White House distributed a list of business executives who would visit with Trump on 11 May, including Elon Musk of Tesla and Tim Cook of Apple Inc. Nvidia CEO Jensen Huang, who had not initially been invited, boarded Air Force One in Alaska to accompany Trump to China. The final list of CEOs included:
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.